

10/509127

Re PCT/PTO 28 SEP 2004
PCT/GB 2003 / 0.0-1-15

INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales

IP10 8QQ

REC'D 22 MAY 2003

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

Dated 9 April 2003

An Executive Agency of the Department of Trade and Industry

BEST AVAILABLE COPY

16/1/1977



The
Patent
Office

09JAN03 E/5571-20 D00056
P01/77000.00-530040019

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

8 JAN 2003

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference	P35060GB/KVC		
2. Patent application number (The Patent Office will fill in this part)	0300400.9		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	Eisai London Research Laboratories Limited Bernard Katz Building University College London Gower Street London WC1E 5BT 85 39785001		
Patents ADP number (if you know it)			
If the applicant is a corporate body, give the country/state of its incorporation	United Kingdom		
4. Title of the invention	JNK Inhibitors		
5. Name of your agent (if you have one)	Kilburn & Strode 20 Red Lion Street London WC1R 4PJ		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)			
Patents ADP number (if you know it)	125001 ✓		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	YES		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 26

Claim(s) 11

Abstract -

Drawing(s) -

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature
Kumam & Strade

Date
8 January 2003

12. Name and daytime telephone number of person to contact in the United Kingdom
Kristina Cornish
Tel: 020 7539 4200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Inhibitors

5 The present invention relates to novel 5-substituted 7-azaindole compounds, their use in the inhibition of c-Jun N-terminal kinases, their use in medicine and particularly in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation. The invention also provides processes for manufacture of said compounds, compositions containing them and processes for manufacturing such compositions.

10 c-Jun N-terminal kinases (hereinafter referred to as "JNKs") are members of the mitogen-activated protein kinase (MAPK) family. JNKs are involved in response to various stimuli, including proinflammatory cytokines and environmental stress. JNKs, and JNK3 in particular, play an important role during apoptotic death of cells and therefore have been implicated in various
15 disorders including stroke, traumatic brain injury and other neurodegenerative diseases such as Parkinson disease, Alzheimer disease and others. Since JNK activity is a physiological regulator of AP-1 transcriptional activity, JNK inhibitors are expected to reduce inflammatory response.

20 Apoptosis is a form of cell death in which the cell actively participates in its own destruction in a process involving a characteristic series of biochemical and morphological changes which are regulated by specific cell death genes (Steller, 1995, Science 267: 1445-1449). The apoptotic cell death is a process that has been observed in the developing mammalian nervous system (Jacobson *et al.*,
25 1997, Cell 88: 347-354). In mice, the inactivation by homologous recombination of genes that encode proteins that promote apoptosis, such as the caspase-3 or the Bax protein, prevents developmental neuronal cell death. The destruction of genes that encode cell death suppressors such as Bcl-x, leads to enhanced neuronal cell death (Motoyama *et al.*, 1995, Science 267: 1506-1510; Deckwerth
30 *et al.*, 1996, Neuron 17: 401-411; Kuida *et al.*, 1996, Nature 384: 368-372). There is increasing evidence that apoptosis plays an important role in the pathology of acute and chronic neurodegenerative diseases (Thompson, 1995, Science 267: 1456-1462; Holtzman and Deshmukh, 1997, Nature Medicine 3:

954-955). For example, in transgenic mice overexpressing the anti-apoptotic Bcl-2 protein in the nervous system there is a decrease in infarct volume following cerebral ischemia (Martinou *et al.*, 1994, *Neuron* 13: 1017-1030). Similarly, injection of the caspase inhibitor BAF reduces neuronal cell death following hypoxia/ischaemia in neonatal rats (Cheng *et al.*, *J Clin Invest.* 1998, 101: 1992-1999). Another example is spinal muscular atrophy (a motor neuron disease) where loss of function mutations in the SMN gene is associated with the disease. Recent data has shown that the wild type SMN protein binds to Bcl-2 and co-operates with it to inhibit apoptosis (Iwahashi *et al.*, 1997, *Nature* 390: 413-417). These results suggest that inhibitors of neuronal apoptosis could be beneficial in the treatment of human neurodegenerative diseases. There is increasing evidence that neuronal apoptosis is an important pathological feature of stroke, traumatic brain injury and other neurodegenerative diseases. Therefore, pharmacotherapy using inhibitors of neuronal apoptosis may provide a therapeutic benefit in neurodegenerative conditions.

A number of groups have studied the mechanisms of neuronal cell death using *in vitro* cell culture systems and the results suggest that in some systems the transcription factor c-Jun is activated by the removal of survival signals and promotes cell death.

Antibodies specific for c-Jun protected NGF-deprived rat sympathetic neurones from apoptosis (Estus *et al.*, 1994, *J. Cell. Biol.* 127: 1717-1727). Analogous neuroprotection due to expression of a c-Jun dominant negative mutant has been demonstrated, whereas overexpression of wild type c-Jun protein was sufficient to induce apoptosis in the presence of NGF (Ham *et al.*, 1995, *Neuron* 14: 927-939). Estus and co-workers recently showed that an increase in c-Jun RNA levels occurs in cortical neurones undergoing apoptosis after treatment with β -amyloid peptide (Estus *et al.*, 1997, *J. Neurosci.* 17, 7736-7745). It has also been shown that c-Jun is required for apoptosis in cerebellar granule neurones deprived of survival signals (Watson *et al.*, 1998, *J. Neurosci.* 18: 751-762).

c-Jun is activated by JNKs, which phosphorylate its transcriptional activation domain. In humans there are three JNK genes : JNK1, JNK2 and JNK3. The RNAs encoding JNK1 and JNK2 are expressed in many tissues, including the brain, but JNK3 is restricted to the nervous system and to a smaller extent the heart and testes.

JNKs are strongly activated in cellular responses to various stresses such as UV radiation, heat shock, osmotic shock, DNA-damaging agents, and proinflammatory cytokines such as TNF α , IL-1 β and others (Whitmarsh *et al.*, 1997, Mol. Cell. Biol. 17: 2360-2371). Upstream regulators of the JNK pathway include kinases such as SEK1, MKK7 and MEKK1. There is evidence that Jun kinase activity is required for neuronal apoptosis *in vitro*. Overexpression of MEKK1 in sympathetic neurones increased c-Jun protein levels and phosphorylation and induced apoptosis in the presence of NGF indicating that activation of the Jun kinase pathway can trigger neuronal cell death (Eilers *et al.*, 1998, J. Neurosci. 18: 1713-1724). The Jun kinase pathway has been shown to be necessary for the death of differentiated PC12 cells deprived of NGF (Xia *et al.*, 1995, Science 270: 1326-1331; Dickens *et al.*, 1997, Science 277: 693-696). Furthermore, compound CEP-1347, which inhibits the c-Jun pathway (upstream of Jun kinase), protects motor neurones against cell death induced by survival factor withdrawal (Maroney *et al.*, 1998, J. Neurosci. 18: 104-111).

In JNK3 homozygous (-/-) knockout mice, epileptic seizures and death of hippocampal CA3 neurones induced by injection of kainic acid is blocked. This indicates that JNK3 is involved in certain forms of neuronal cell death *in vivo*. It is also a critical component of GluR6-mediated excitotoxicity (Savinainen *et al.* J Biol Chem, 276,11382-11386 (2001)). Furthermore, JNK3 (-/-) mice appear to develop normally and are viable suggesting that JNK3 is not essential for development or viability.

Strong nuclear JNK3 immunoreactivity in the brain CA1 neurones of patients with acute hypoxia suggests that JNK3 is involved in hypoxia-related neurodegeneration. (Zhang *et al.* Proc Natl Acad Sci U S A 1998 Mar


3;95(5):2586-91). Transient hypoxia, may also trigger apoptosis through JNK signaling pathway in developing brain neurones. (Chihab *et al.* Brain Res Mol Brain Res 1998 Dec 10;63(1):105-20)

5 Furthermore, JNK3 immunoreactivity is colocalized with Alzheimer disease-affected neurones (Mohit *et al.* Neuron 1995 Jan;14(1):67-78). Moreover JNK3 is related to neurofibrillary pathology of Alzheimer disease (Zhu *et al.* J Neurochem 2001 Jan;76(2):435-441). In particular, JNK3 induces robust phosphorylation of amyloid precursor protein (APP) thus affecting its
10 metabolism in disease state (Standen *et al.* J Neurochem 2001 Jan; 76(1):316-20).

The present inventors have provided compounds which are inhibitors of c-Jun N-terminal kinases.

15

The present invention relates to a compound of formula I as defined below:



20

wherein:

25 R stands for carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein

the optionally substituted carbocyclyl or optionally substituted heterocyclyl group is optionally fused to an unsaturated, partially unsaturated or fully saturated five to seven membered ring containing zero to three heteroatoms,
30 each substitutable carbon atom in R, including the optional fused ring, is optionally and independently substituted by one or more of C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, carbocyclyl, or heterocyclyl, halogen, haloalkyl, OR², SR², NO₂, CN, NR²R², NR²COR², NR²CONR²R², NR²COR², NR²CO₂R², CO₂R², COR², CONR²R², S(O)₂R², SONH₂, S(O)R², SO₂NR²R²,

$\text{NR}^2\text{S}(\text{O})_2\text{R}^2$, wherein each R^2 may be the same or different and is as defined below and wherein:

5 the C_{1-12} alkyl optionally incorporates one or two insertions selected from the group consisting of $-\text{O}-$, $-\text{C}(\text{O})-$, $-\text{N}(\text{R}^2)-$, $-\text{S}(\text{O})-$ and $-\text{S}(\text{O}_2)-$ wherein each R^2 may be the same or different and is as defined below;

10 the C_{1-12} alkyl, carbocyclyl, or heterocyclyl group is optionally substituted by one or more of halogen, haloalkyl, OR^2 , SR^2 , NO_2 , CN , NR^2R^2 , NR^2COR^2 , $\text{NR}^2\text{CONR}^2\text{R}^2$, NR^2COR^2 , $\text{NR}^2\text{CO}_2\text{R}^2$, CO_2R^2 , COR^2 , CONR^2_2 , $\text{S}(\text{O})_2\text{R}^2$, SONH_2 , $\text{S}(\text{O})\text{R}^2$, $\text{SO}_2\text{NR}^2\text{R}^2$, $\text{NR}^2\text{S}(\text{O})_2\text{R}^2$; wherein each R^2 may be the same or different and is as defined below and

15 the carbocyclyl, or heterocyclyl group is optionally substituted by one or more C_{1-12} alkyl, each saturated carbon in the optional fused ring is further optionally and independently substituted by $=\text{O}$, $=\text{S}$, $=\text{NNHR}^2$, NNR^2R^2 , $=\text{N}-\text{OR}^2$, $=\text{NNH}\text{COR}^2$, $=\text{NNH}\text{CO}_2\text{R}^2$, $=\text{NNSO}_2\text{R}^2$, or $=\text{NR}^2$, wherein each R^2 may be the same or different and is as defined below; and each substitutable nitrogen atom in R is optionally substituted by R^3 , COR^2 , SO_2R^2 or CO_2R^2 , wherein each R^2 and R^3 may be the same or different and is as defined below;

25 R^2 is hydrogen, C_{1-12} alkyl or aryl, optionally substituted by one or more of C_{1-4} alkyl, halogen, C_{1-4} haloalkyl, OR^4 , SR^4 , NO_2 , CN , NR^4R^4 , NR^4COR^4 , $\text{NR}^4\text{CONR}^4\text{R}^4$, NR^4COR^4 , $\text{NR}^4\text{CO}_2\text{R}^4$, CO_2R^4 , COR^4 , CONR^4_2 , $\text{S}(\text{O})_2\text{R}^4$, SONH_2 , $\text{S}(\text{O})\text{R}^4$, $\text{SO}_2\text{NR}^4\text{R}^4$, $\text{NR}^4\text{S}(\text{O})_2\text{R}^4$, wherein the C_{1-12} alkyl group optionally incorporates one or two insertions selected from the group consisting of $-\text{O}-$, $-\text{N}(\text{R}^4)-$, $-\text{S}(\text{O})-$ and $-\text{S}(\text{O}_2)-$, wherein each R^4 may be the same or different and is as defined below;

30 R^3 is C_{1-12} alkyl or aryl, optionally substituted by one or more of C_{1-4} alkyl, halogen, C_{1-4} haloalkyl, OR^4 , SR^4 , NO_2 , CN , NR^4R^4 , NR^4COR^4 , $\text{NR}^4\text{CONR}^4\text{R}^4$, NR^4COR^4 , $\text{NR}^4\text{CO}_2\text{R}^4$, CO_2R^4 , COR^4 , CONR^4_2 , $\text{S}(\text{O})_2\text{R}^4$, SONH_2 , $\text{S}(\text{O})\text{R}^4$, $\text{SO}_2\text{NR}^4\text{R}^4$, $\text{NR}^4\text{S}(\text{O})_2\text{R}^4$, wherein the C_{1-12} alkyl group optionally incorporates one or two insertions selected from the group

consisting of -O-, -N(R⁴)-, -S(O)- and -S(O₂)-, wherein each R⁴ may be the same or different and is as defined below;

R⁴ is hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl;

5 and the pharmaceutically acceptable salts, and other pharmaceutically acceptable biohydrolyzable derivatives thereof, including esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents or prodrugs thereof.

10 For the avoidance of doubt, when a group as defined above contains two or more radicals, e.g. the radical R², as for example in the groups SO₂NR²R² and NR²COR², the radicals R² may be the same or different.

15 For the purposes of this invention, "alkyl" means a straight chain or branched alkyl radical of 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms and most preferably 1 to 4 carbon atoms including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl etc. The term "alkenyl" means a straight chain or branched alkylenyl radical of 2 to 12 carbon atoms, preferably 2 to 6 carbon atoms and most preferably 2 to 4 carbon atoms, and containing one or more carbon-carbon double bonds and includes but is not
20 limited to ethylene, n-propyl-1-ene, n-propyl-2-ene, isopropylene, etc.. The term "alkynyl" means a straight chain or branched alkynyl radical of 2 to 12 carbon atoms, preferably 2 to 6 carbon atoms and most preferably 2 to 4 carbon atoms, and containing one or more carbon-carbon triple bonds and includes but is not
25 saturated or partly unsaturated 3-12 membered cyclic alkyl group and includes but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl etc.. Cycloalkyl groups may be optionally substituted or fused to one or more aryl, heterocyclyl or cycloalkyl group. "Heterocycloalkyl" means a 3-12 membered saturated or partly unsaturated cycloalkyl containing one or more hetero atom
30 selected from N, S and O. "Haloalkyl" means an alkyl radical substituted with one or more halide atoms for example CH₂CH₂Br, CF₃ or CCl₃.

"Carbocyclyl" relates to a saturated, partly unsaturated or unsaturated 3-10 membered hydrocarbon ring, including cycloalkyl and aryl.

5 "Aryl" means an aromatic 3-10 membered hydrocarbon containing one ring or being fused to one or more saturated or unsaturated rings including but not limited to phenyl, naphthyl, anthracenyl or phenanthracenyl.

"Heteroaryl" means an aromatic 3-10 membered aryl containing one or more heteroatoms selected from N, O or S and containing one ring or being fused to
10 one or more saturated or unsaturated rings and.

"Heterocyclyl" means a 3-10 membered ring system containing one or more heteroatoms selected from N, O or S and includes heteroaryl. The heterocyclyl system can contain one ring or may be fused to one or more saturated or
15 unsaturated rings; the heterocyclyl can be fully saturated, partially saturated or unsaturated and includes but is not limited heteroaryl and heterocarbocyclyl, e.g. cyclohexyl, phenyl, acridine, benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, carbazole, cinnoline, dioxin, dioxane, dioxolane, dithiane, dithiazine, dithiazole, dithiolane, furan, imidazole, imidazoline,
20 imidazolidine, indole, indoline, indolizine, indazole, isoindole, isoquinoline, isoxazole, isothiazole, morpholine, naphthyridine, oxazole, oxadiazole, oxathiazole, oxathiazolidine, oxazine, oxadiazine, phenazine, phenothiazine, phenoxazine, phthalazine, piperazine, piperidine, pteridine, purine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine,
25 pyrrole, pyrrolidine, pyrroline, quinoline, quinoxaline, quinazoline, quinolizine, tetrahydrofuran, tetrazine, tetrazole, thiophene, thiadiazine, thiadiazole, thiatriazole, thiazine, thiazole, thiomorpholine, thianaphthalene, thiopyran, triazine, triazole, and trithiane;

30 Halogen means F, Cl, Br or I, preferably F.

R is preferably substituted with one or more of alkyl (e.g. methyl, ethyl or propyl), haloalkyl (preferably CF₃), halogen (e.g. F, Cl or Br, preferably F), OR⁸,

SR^8 , SOR^8 , $(NR^8)_2$, wherein R^8 is independently selected from hydrogen, C_{1-4} alkyl or haloalkyl and is preferably phenyl or naphthyl. When R is phenyl it is preferably substituted in the 4-(para) position, e.g. by $NR^6 R^6$, where R^6 stands independently for H or C_{1-4} alkyl.

5

Representative compounds according to the first aspect of the invention are illustrated below.

5


10

15







20

25







30









5









10









15




20



25



30




The compounds of the invention may be provided as a salt, preferably as a pharmaceutically acceptable salt of compounds of formula I. Examples of pharmaceutically acceptable salts of these compounds include those derived from organic acids such as acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, mandelic acid, methanesulphonic acid, benzenesulphonic acid and p-toluenesulphonic acid, mineral acids such as hydrochloric and sulphuric acid and the like, giving methanesulphonate, benzenesulphonate, p-toluenesulphonate, hydrochloride and sulphate, and the like, respectively or those derived from bases such as organic and inorganic bases. Examples of suitable inorganic bases for the formation of salts of compounds for this invention include the hydroxides, carbonates, and bicarbonates of ammonia, lithium, sodium, calcium, potassium, aluminium, iron, magnesium, zinc and the like. Salts can also be formed with suitable organic bases. Such bases suitable for the formation of pharmaceutically acceptable base addition salts with compounds of the present invention include organic bases which are nontoxic and strong enough to form salts. Such organic bases are already well known in the art and may include amino acids such as arginine and lysine, mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine, choline, mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and trimethylamine, guanidine; N-methylglucosamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; tris(hydroxymethyl) aminomethane; and the like.

Salts may be prepared in a conventional manner using methods well known in the art. Acid addition salts of said basic compounds may be prepared by dissolving the free base compounds according to the first or second aspects of the invention in aqueous or aqueous alcohol solution or other suitable solvents containing the required acid. Where a compound of the invention contains an acidic function, a base salt of said compound may be prepared by reacting said compound with a suitable base. The acid or base salt may separate directly or can be obtained by concentrating the solution e.g. by evaporation. The compounds of this invention may also exist in solvated or hydrated forms.


The invention also extends to a prodrug of the aforementioned compounds. A prodrug is any compound that may be converted under physiological conditions or by solvolysis to any of the compounds of the invention or to a pharmaceutically acceptable salt of the compounds of the invention. A prodrug may be inactive when administered to a subject but is converted *in vivo* to an active compound of the invention.

The compounds of the invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. The first aspect of the invention covers all of these compounds.

In accordance with the present invention, the compound of the general formula I:



can be made by hydrogenating a compound of the general formula II:




25

in which R is as defined above and hal stands for a halogen atom, principally F or Cl, e.g. using in the presence of a suitable metal catalyst, such as e.g. palladium on activated carbon, and suitable amine such as e.g. triethylamine. The reaction can be run using a solution of compound II in a single solvent (e.g. alcohol, such as methanol or ethanol) or a mixture of solvents including e.g. an alcohol, dichloromethane, chloroform, etc..

30


13



5

The compound of the general formula II can be made by halogenating a compound of the general formula III in the 2 position, e.g.:

10




15

where R is as defined above, e.g. using $P(O)Cl_3$ at elevated temperature (about $100^\circ C$).

20

The compound of the general formula III can be made from 7-azaindole according to processes known in the art, see for example Glennon, K. C. *et al.* (WO00/56710) and Viaud, M.-C. *et al.* (EP0737685) and Cheung, M. *et al.* (WO99/21859). An example of a suitable scheme for the production of the compound of the general formula III is:



25

The present invention also provides a composition comprising a compound of the general formula I as defined above in combination with a pharmaceutically acceptable carrier, diluent or excipient.

30

The composition may also comprise one or more additional active agent, such as an anti-inflammatory agent (for example a p38 inhibitor, glutamate receptor

antagonist, or a calcium channel antagonist), a chemotherapeutic agent and/or an antiproliferative agent.

Suitable carriers and/or diluents are well known in the art and include
5 pharmaceutical grade starch, mannitol; lactose, magnesium stearate, sodium
saccharin, talcum, cellulose, glucose, sucrose, (or other sugar), magnesium
carbonate, gelatin, oil, alcohol, detergents, emulsifiers or water (preferably
sterile). The composition may be a mixed preparation of a composition or may
be a combined preparation for simultaneous, separate or sequential use
10 (including administration).

The composition according to the invention for use in the aforementioned
indications may be administered by any convenient method, for example by oral
(including by inhalation), parenteral, mucosal (e.g. buccal, sublingual, nasal),
15 rectal or transdermal administration and the compositions adapted accordingly.

For oral administration, the composition can be formulated as liquids or solids,
for example solutions, syrups, suspensions or emulsions, tablets, capsules and
lozenges.

20 A liquid formulation will generally consist of a suspension or solution of the
compound or physiologically acceptable salt in a suitable aqueous or non-
aqueous liquid carrier(s) for example water, ethanol, glycerine, polyethylene
glycol or an oil. The formulation may also contain a suspending agent,
25 preservative, flavouring or colouring agent.

A composition in the form of a tablet can be prepared using any suitable
pharmaceutical carrier(s) routinely used for preparing solid formulations.
Examples of such carriers include magnesium stearate, starch, lactose, sucrose
30 and microcrystalline cellulose.

A composition in the form of a capsule can be prepared using routine
encapsulation procedures. For example, powders, granules or pellets containing

the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

Compositions for oral administration may be designed to protect the active ingredient against degradation as it passes through the alimentary tract, for example by an outer coating of the formulation on a tablet or capsule.

10

Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous or non-aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

15

Compositions for nasal or oral administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a pharmaceutically acceptable propellant. The aerosol dosage forms can also take the form of a pump-atomiser.

20

25

30

Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

Compositions for rectal or vaginal administration are conveniently in the form of suppositories (containing a conventional suppository base such as cocoa butter), pessaries, vaginal tabs, foams or enemas.

5

~~Compositions suitable for transdermal administration include ointments, gels,~~
patches and injections including powder injections.

10

Conveniently the composition is in unit dose form such as a tablet, capsule or ampoule.

15

In addition, the present invention provides a process for the manufacture of a composition according to the invention, as described above. The manufacture can be carried out by standard techniques well known in the art and involves combining a compound according to the first aspect of the invention and the pharmaceutically acceptable carrier or diluent. The composition may be in any form including a tablet, a liquid, a capsule, and a powder or in the form of a food product, e.g. a functional food. In the latter case the food product itself may act as the pharmaceutically acceptable carrier.

20

In addition, the present invention relates to a compound of the general formula I or a composition containing the compound, for use in therapy/medicine.

25

The compounds of the present invention are inhibitors of JNK, such as JNK1, JNK2, or JNK3. In particular, the compounds of the present invention are inhibitors of JNK3. Preferably, the compounds of the present invention inhibit JNK3 specifically.

30

One advantage of the compounds of the present invention is that they show a good stability to liver microsomes, at least when tested *in vitro* and hence are not rapidly metabolically removed from the body.

The compounds are therefore useful for conditions for which inhibition of JNK activity is beneficial. Thus, preferably, this aspect provides a compound of the general formula I, or a composition of the present invention, as described above, for the prevention or treatment of a JNK-mediated disorder. The compounds of the general formula I may thus be used for the inhibition of JNK, more preferably for the inhibition of JNK3.

A "JNK-mediated disorder" is any disease or deleterious condition in which JNK plays a role. Examples include neurodegenerative disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis, autoimmune disease, destructive bone disorder, proliferative disorder, cancer, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin induced platelet aggregation and any condition associated with prostaglandin endoperoxidase synthase-2. The compounds of the present invention may be used for any of these JNK-mediated disorders.

The compounds of the present invention are particularly useful for the prevention or treatment of a neurodegenerative disorder. In particular, the neurodegenerative disorder results from apoptosis and/or inflammation. Examples of neurodegenerative disorders are: dementia; Alzheimer's disease; Parkinson's disease; Amyotrophic Lateral Sclerosis; Huntington's disease; senile chorea; Sydenham's chorea; hypoglycemia; head and spinal cord trauma including traumatic head injury; acute and chronic pain; epilepsy and seizures; olivopontocerebellar dementia; neuronal cell death; hypoxia-related neurodegeneration; acute hypoxia; glutamate toxicity including glutamate neurotoxicity; cerebral ischemia; dementia linked to meningitis and/or neurosis; cerebrovascular dementia; or dementia in an HIV-infected patient.

The neurodegenerative disorder may be a peripheral neuropathy, including mononeuropathy, multiple mononeuropathy or polyneuropathy. Examples of peripheral neuropathy may be found in diabetes mellitus, Lyme disease or uremia; peripheral neuropathy caused by a toxic agent; demyelinating disease

such as acute or chronic inflammatory polyneuropathy, leukodystrophies, or Guillain-Barré syndrome; multiple mononeuropathy secondary to a collagen vascular disorder (e.g. polyarteritis nodosa, SLE, Sjögren's syndrome); multiple mononeuropathy secondary to sarcoidosis; multiple mononeuropathy secondary to a metabolic disease (e.g. diabetes or amyloidosis); or multiple mononeuropathy secondary to an infectious disease (e.g. Lyme disease or HIV infection).

The compounds of the invention can also be used to prevent or treat disorders resulting from inflammation. These include, for example, inflammatory bowel disorder, bronchitis, asthma, acute pancreatitis, chronic pancreatitis, allergies of various types, and possibly Alzheimer's disease. Autoimmune diseases which may also be treated or prevented by the compounds of the present invention include rheumatoid arthritis, systemic lupus erythematosus, glomerulonephritis, scleroderma, chronic thyroiditis, Graves's disease, autoimmune gastritis, diabetes, autoimmune haemolytic anaemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis or graft vs host disease.

A compound of the present invention may be administered simultaneously, subsequently or sequentially with one or more other active agent, such as an anti-inflammatory agent e.g. p38 inhibitor, glutamate receptor antagonist, calcium channel antagonist, a chemotherapeutic agent or an antiproliferative agent. For example, for acute treatment, a p38 inhibitor may be administered to a patient prior to administering a compound of the present invention.

The compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 2000 mg, preferably between 30 mg and 1000 mg, e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the formula (I) or a physiologically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per

day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more.

5 Accordingly the present invention relates to a method of treating or preventing a JNK-mediated disorder in an individual, which method comprises administering to said individual a compound of the first aspect or a composition containing that compound. aspect. The active compound is preferably administered in a cumulative effective amount. The individual may be in need of the treatment or prevention. Any of the JNK-mediated disorders listed above in relation to the 10 sixth aspect may be the subject of treatment or prevention according to the seventh aspect. One or more other active agent may be administered to the individual simultaneously, subsequently or sequentially to administering the compound. The other active agent may be an anti-inflammatory agent such as a p38-inhibitor, glutamate receptor antagonist, calcium channel antagonist, a 15 chemotherapeutic agent or an antiproliferative agent, but is preferably p38 inhibitor for acute treatment.

20 The present invention provides the use of a compound of the general formula I in the manufacture of a medicament for the prevention or treatment of a JNK-mediated disorder. The medicament may be used for treatment or prevention of any of the JNK-mediated disorders listed above in relation to the sixth aspect. Again, the compound of the present invention may be administered simultaneously, subsequently or sequentially with one or more other active 25 agent, preferably a p38 inhibitor for acute treatment.

30 According to the present invention, there is also provided an assay for determining the activity of the compounds of the present invention, comprising providing a system for assaying the activity and assaying the activity of the compound. Preferably the assay is for the JNK inhibiting activity of the compound, more preferably it is for the JNK3-specific inhibiting activity of the compounds. The compounds of the invention may be assayed *in vitro*, *in vivo*, *in silico*, or in a primary cell culture or a cell line. *In vitro* assays include assays

that determine inhibition of either the kinase activity or ATPase activity of activated JNK. Alternatively, *in vitro* assays may quantitate the ability of a compound to bind JNK and may be measured either by radiolabelling the compound prior to binding, then isolating the inhibitor/JNK complex and
5 determining the amount of the radiolabel bound or by running a competition experiment where new inhibitors are incubated with JNK bound to known radioligands. An example of an assay which may be used is Scintillation Proximity Assay (SPA), preferably using radiolabelled ATP. Another example is ELISA. Any type or isoform of JNK may be used in these assays.

10


In a yet further aspect of the present invention, there is provided a method of inhibiting the activity or function of a JNK, particularly JNK3, which method comprises exposing a JNK to a compound or a composition of the first or fourth aspect of the present invention. The method may be performed in a research
15 model, *in vitro*, *in silico*, or *in vivo* such as in an animal model. A suitable animal model may be a kainic acid model in rat or mice, traumatic brain injury model in rat, or MPTP in mice.

All features of each of the aspects apply to all other aspects *mutatis mutandis*.


20

Below, the present invention is illustrated using non-limiting examples.

EXAMPLES

Synthesis of example 5-substituted 7-azaindole derivative 7


Scheme 1

3,3-Dibromo-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (2)

Technical (90%) pyridinium tribromide (220.4 g, 0.62 mol) was added portionwise over a period of 30 min to a stirred suspension of 7-azaindole (1, 27.13 g, 0.23 mol) in *t*-BuOH (1.36 L). The mixture was stirred at r.t for 3 h, and more pyridinium tribromide (73.3 g, 0.21 mol) was added in one portion. After additional stirring at r.t. for 2 h, the solvent was evaporated under reduced pressure. The residue was separated between water:AcOEt=1:1 (4.2 L). The aqueous layer was extracted with AcOEt (2x800 mL). Combined organic solutions were washed with water (2x500 mL), brine, dried (MgSO₄) and concentrated to dryness in vacuum. The residue was triturated with CH₂Cl₂ (1500 mL) for 20 min. The solid was filtered off, washed with CH₂Cl₂ (250 mL) and dried in vacuum to afford 2 (49.85 g, 75%) as yellow powder. ¹H NMR (400

MHz, DMSO- d_6) δ 7.16 (dd, $J = 7.4, 5.1$ Hz, 1H), 7.98 (dd, $J = 7.4, 1.5$ Hz, 1H), 8.19 (dd, $J = 5.1, 1.5$ Hz, 1H), 11.97 (bs, 1H).


3,3,5-Tribromo-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (3)



5

Bromine (13.4 mL, 0.262 mol) was added dropwise over a period of 30 min to a cooled (ice bath) and stirred suspension of 2 (37.86 g, 0.131 mol) in water: t -BuOH=1:1 (1500 mL). Cooling bath was removed and the mixture was stirred at r.t. overnight. Then the solution was cooled to 15 °C and saturated aqueous solution of NaHCO₃ (278 mL) was added. A yellow suspension, which was formed, was concentrated in vacuum (bath temperature < 32 °C) until about 1000 mL of condensate was collected. The solid was filtered off, washed with water (200 mL), and dried in vacuum to afford 3 (40.85 g, 85%) as tan powder.

5-Bromo-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (4)



15

Zinc dust (34.0 g, 0.52 mol) was added in small portion to a stirred suspension of 3 (40.85 g, 0.111 mol) in glacial acetic acid (1000 mL) at such a rate that the temperature was maintained between 20-25 °C (strongly exothermic reaction; external ice bath cooling). Addition took about 20 min. Cooling bath was removed and stirring was continued at r.t. for 2 h. The solid was filtered off, washed with toluene (50 mL) and triturated with CH₂Cl₂:MeOH=4:1 (2.5 L). The solution was decanted off and treated with 1.0 M aqueous Na₂CO₃ solution (170 mL). After stirring for 1 h the two layers were separated. The organic layer was washed again with 1.0 M aqueous Na₂CO₃ solution (50 mL). The combined aqueous layers were extracted with CH₂Cl₂:MeOH=4:1 (10x100 mL). Combined organic solutions were dried with MgSO₄ (200 g) and concentrated. The residual


20

25

solid was dissolved in THF (2000 mL) and insoluble material was filtered off. The filtrate was concentrated to dryness in vacuum to afford 4 (16.93 g, 72%) as tan solid. ^1H NMR (400 MHz, DMSO- d_6) δ 3.57 (s, 2H), 7.75 (m, 1H), 8.14 (m, 1H), 11.13 (bs, 1H).

5


5-(3-Fluoro-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (5)



A mixture of 4 (16.63 g, 78.5 mmol), 3-fluorophenylboronic acid (16.47 g, 117.7 mmol), $\text{Pd(PPh}_3)_2\text{Cl}_2$ (2.73 g, 6.60 mmol), LiCl (9.95 g, 0.23 mol), 1.0 M aqueous Na_2CO_3 solution (196 mL, 0.196 mol) in EtOH (470 mL) – toluene (470 mL) was refluxed overnight. More $\text{Pd(PPh}_3)_2\text{Cl}_2$ (1.30 g, 3.14 mmol) was added and reflux was continued for 24 h. The mixture was cooled, and the organic layer was separated and washed with brine (100 mL). The washings were combined with the aqueous layer and extracted with AcOEt (4x400 mL). Combined extracts were washed with brine, added to the organic layer and dried with MgSO_4 . The solution was concentrated to dryness in vacuum to give 26.98 g of brown semisolid, which was triturated with ether:hexane=1:1 (2x500 mL). The residue was dried in vacuum to afford 5 (16.85 g, 94%) as tan solid, which was used in the next step without further purification. ^1H NMR (400 MHz, CDCl_3) δ 3.66 (s, 2H), 7.08 (dddd, J = 8.4, 8.2, 2.4, 0.9 Hz, 1H), 7.22 (ddd, J = 10.0, 2.4, 1.7 Hz, 1H), 7.30 (ddd, J = 8.1, 1.7, 0.9 Hz, 1H), 7.43 (ddd, J = 8.2, 8.1, 6.0 Hz, 1H), 7.69 (s, 1H), 8.36 (d, J = 2.1 Hz, 1H), 8.98 (bs, 1H).


20

2-Chloro-5-(3-fluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine (6)



A suspension of **5** (16.52 g, 72.4 mmol) in neat P(O)Cl_3 (21.5 mL, 0.231 mol) was stirred at 100-105 °C for 4 h. The mixture was then cooled to r.t., diluted with *p*-xylene (100 mL) and concentrated to dryness in vacuum. The residue was separated between saturated aqueous NaHCO_3 – AcOEt. 10% aqueous solution of Na_2CO_3 was added to basify the aqueous layer to pH 9. Organic phase was separated and the aqueous layer was extracted with AcOEt (8x300 mL). Combined organic solutions were dried MgSO_4 , concentrated, and the residue was purified by silicagel chromatography (SGC) using CH_2Cl_2 :AcOEt as eluent in gradient to afford recovered starting material **5** (0.76 g, 5%). The desired product was then crystallized from acetone to afford **6** (10.06 g, 56%), thin tan needles. ^1H NMR (400 MHz, CDCl_3) δ 6.47 (s, 1H), 7.08 (tdd, $J = 8.1, 2.3, 1.5$ Hz, 1H), 7.33 (ddd, $J = 9.9, 2.3, 1.6$ Hz, 1H), 7.38-7.48 (m, 2H), 8.03 (d, $J = 2.1$ Hz, 1H), 8.53 (d, $J = 2.1$ Hz, 1H), 11.46 (bs, 1H).

5-(3-Fluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine (**7**)



A mixture of chloride **6** (5.23 g, 21.3 mmol), 10% Pd/C (2.7 g), Et_3N (3.6 mL, 25.8 mmol) in THF:MeOH=5:1 (180 mL) was stirred under H_2 overnight. More 10% Pd/C (1.3 g) was added and stirring was continued for 3 h. Catalyst was removed by filtration and the solution was concentrated to dryness in vacuum. The residue was purified by SGC with CH_2Cl_2 :AcOEt as eluent in gradient (up to 20% AcOEt) to afford **7** (5.23 g, 88%), greenish powder. ^1H NMR (400 MHz, CDCl_3) δ 6.59 (dd, $J = 3.5, 2.0$ Hz, 1H), 7.04-7.10 (m, 1H), 7.33-7.37 (m, 1H),

7.40-7.48 (m, 3H), 8.14 (d, $J = 2.1$ Hz, 1H), 8.57 (d, $J = 2.1$ Hz, 1H), 9.91 (bs, 1H).

JNK1, JNK2, JNK3 - SPA assay

5

A typical assay for testing the activity of compounds to inhibit JNK1, JNK2 and JNK3 enzymes is as follows:

- 10 1. Compound is dissolved in DMSO to a convenient concentration and this is diluted in 10% DMSO to a five times concentrate of the desired starting concentration (frequently 1:100).
2. 10 μ l of 500 mM EDTA is added to alternative wells of the Opti-plate row, which will receive kinase reaction plus DMSO. This creates the negative control.
- 15 3. For the JNK2 and JNK3 assay, compounds are prepared in six 2-fold dilutions with water and each concentration is tested in duplicate. For the JNK1 assay compounds are prepared in four 5-fold dilutions with water which are tested in triplicate. Controls are treated identically.
4. 20 μ l per well of each compound concentration is transferred to an Opti-plate, in duplicate.
- 20 5. 30 μ l (JNK2/3 SPA) or 50 μ l (JNK1 SPA) of substrate solution (25 mM HEPES pH 7.5, 10mM magnesium acetate with 3.33 μ M ATP (JNK2/3) or 2 μ M ATP (JNK1), approximately 7.5 kBq [γ -33P] ATP, GST-c-Jun, in water) is added to each well.
- 25 6. 50 μ l (JNK2/3 SPA) or 30 μ l (JNK1 SPA) of kinase solution (JNK in 25 mM HEPES pH 7.5, 10mM Mg Acetate) is added to each well.



Kinase	Kinase per well (μ g)	GST-c-Jun per well (μ g)
JNK1	0.25	1
JNK2	0.2	1.2
JNK3	0.16	1.2

7. The plate is incubated for 30 minutes at room temperature.
8. 100 μ l of bead/stop solution is added to each well (5 mg/ml glutathione-PVT-SPA beads, 40 mM ATP in PBS).

9. Plates are sealed and incubated for 30 minutes at room temperature, centrifuged for 10 minutes at 2500g and counted.
10. The IC_{50} values are calculated as the concentration of the compound being tested at which the phosphorylation of c-Jun is decreased to 50% of the control value. Example IC_{50} values for the compounds of this invention are given in Table 1.


Examples of inhibitory potency against JNK3 kinase

10 Table 1. IC_{50} values for selected compounds against JNK3 kinase

Compound Number	Structure	JNK3 IC_{50} (μ M)
1		0.73
2		<1

Claims

1. A compound of formula I as defined below:



wherein:

10 R stands for carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl, wherein

the optionally substituted carbocyclyl or optionally substituted heterocyclyl group is optionally fused to an unsaturated, partially unsaturated or fully saturated five to seven membered ring containing zero to three heteroatoms,

15 each substitutable carbon atom in R, including the optional fused ring, is optionally and independently substituted by one or more of C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, carbocyclyl, or heterocyclyl, halogen, haloalkyl, OR², SR², NO₂, CN, NR²R², NR²COR², NR²CONR²R², NR²COR², NR²CO₂R², CO₂R², COR², CONR²R², S(O)₂R², SONH₂, S(O)R², SO₂NR²R², NR²S(O)₂R², wherein each R² may be the same or different and is as defined below and wherein:

25 the C₁₋₁₂ alkyl optionally incorporates one or two insertions selected from the group consisting of -O-, -C(O)-, -N(R²)-, -S(O)- and -S(O)₂- wherein each R² may be the same or different and is as defined below;

30 the C₁₋₁₂ alkyl, carbocyclyl, or heterocyclyl group is optionally substituted by one or more of halogen, haloalkyl, OR², SR², NO₂, CN, NR²R², NR²COR², NR²CONR²R², NR²COR², NR²CO₂R², CO₂R², COR², CONR²R², S(O)₂R², SONH₂, S(O)R², SO₂NR²R², NR²S(O)₂R²; wherein each R² may be the same or different and is as defined below and

the carbocyclyl, or heterocyclyl group is optionally substituted by one or more C_{1-12} alkyl,

each saturated carbon in the optional fused ring is further optionally and independently substituted by $=O$, $=S$, $=NNHR^2$, NNR^2R^2 , $=N-OR^2$, $=NNHCOR^2$, $=NNHCO_2R^2$, $=NNSO_2R^2$, or $=NR^2$, wherein each R^2 may be the same or different and is as defined below; and

each substitutable nitrogen atom in R is optionally substituted by R^3 , COR^2 , SO_2R^2 or CO_2R^2 , wherein each R^2 and R^3 may be the same or different and is as defined below;

R^2 is hydrogen, C_{1-12} alkyl or aryl, optionally substituted by one or more of C_{1-4} alkyl, halogen, C_{1-4} haloalkyl, OR^4 , SR^4 , NO_2 , CN , NR^4R^4 , NR^4COR^4 , $NR^4CONR^4R^4$, NR^4COR^4 , $NR^4CO_2R^4$, CO_2R^4 , COR^4 , $CONR^4_2$, $S(O)_2R^4$, $SONH_2$, $S(O)R^4$, $SO_2NR^4R^4$, $NR^4S(O)_2R^4$, wherein the C_{1-12} alkyl group optionally incorporates one or two insertions selected from the group consisting of $-O-$, $-N(R^4)-$, $-S(O)-$ and $-S(O_2)-$, wherein each R^4 may be the same or different and is as defined below;

R^3 is C_{1-12} alkyl or aryl, optionally substituted by one or more of C_{1-4} alkyl, halogen, C_{1-4} haloalkyl, OR^4 , SR^4 , NO_2 , CN , NR^4R^4 , NR^4COR^4 , $NR^4CONR^4R^4$, NR^4COR^4 , $NR^4CO_2R^4$, CO_2R^4 , COR^4 , $CONR^4_2$, $S(O)_2R^4$, $SONH_2$, $S(O)R^4$, $SO_2NR^4R^4$, $NR^4S(O)_2R^4$, wherein the C_{1-12} alkyl group optionally incorporates one or two insertions selected from the group consisting of $-O-$, $-N(R^4)-$, $-S(O)-$ and $-S(O_2)-$, wherein each R^4 may be the same or different and is as defined below;


R^4 is hydrogen, C_{1-4} alkyl, or C_{1-4} haloalkyl;

and the pharmaceutically acceptable salts, and other pharmaceutically acceptable biohydrolyzable derivatives thereof, including esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents or prodrugs thereof.


2. A compound as claimed in claim 1, wherein R is an aryl or heteroaryl radical, optionally substituted with one or more of alkyl, haloalkyl, halogen, OR^8 , SR^8 , SO_2R^8 , $(NR^8)_2$, wherein R^8 is independently selected from hydrogen, C_{1-4} alkyl or haloalkyl.

3. A compound as claimed in claim 1 wherein R is an optionally substituted aryl, preferably phenyl or naphthyl.
4. A compound as claimed in claim 3, wherein R is phenyl substituted in the 4-(para) position.
5. A compound as claimed in claim 3 or claim 4, wherein R is phenyl substituted by NR^6 R^6 , where R^6 stands independently for H or C_{1-4} alkyl.
6. A compound as claimed in claim 3 or claim 4, wherein R is substituted aryl and the substituent is F, Cl or Br, preferably F; or haloalkyl, preferably CF_3 , or alkyl, preferably methyl, ethyl or propyl.
7. A compound as claimed in claim 1, which is one of the following:


15




20




25




30






8. A prodrug of a compound as defined in any of claims 1 to 7.

9. A process for the manufacture of any one or more of the compounds of any one of claims 1 to 7 which comprises hydrogenating a compound of the general formula II:



10 in which R is as defined in claim 1 and hal stands for a halogen atom, e.g. using hydrogen and a catalyst such as Pd-C.

10. A process as claimed in claim 9, wherein the compound of the general formula II is made by halogenating a compound of the general formula III in the 2 position



20 where R is as defined above and hal stands for halogen, e.g. using $P(O)Cl_3$ at elevated temperature (about $100^\circ C$).

11. A composition comprising a compound as defined in any of claims 1-7 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

25

12. A composition as claimed in claim 11 further comprising one or more other active agent.

13.. A composition as claimed in claim 11 wherein the composition further comprises an anti-inflammatory agent, for example a p38 inhibitor.

30

14. A process for the manufacture of a composition as defined in any of claims 11-13, comprising combining a compound as defined in any of claims 1-

7, and any additional active agent, with the pharmaceutically acceptable carrier or diluent.

15. A compound as defined in any of claims 1-7, or a composition as defined
5 in any of claims 11-13, for use in therapy.

16. A compound as defined in any of claims 1-7, or a composition as defined
in any of claims 11-13, for inhibiting JNK.

10 17. A compound as defined in any of claims 1-7, or a composition as defined
in any of claims 11-13, for selectively inhibiting JNK3.

18. A compound as defined in any of claims 1-7, or a composition as defined
in any of claims 11-13, for use in the prevention or treatment of a JNK-mediated
15 disorder.

19. A compound or a composition as claimed in claim 18, wherein the
disorder is a neurodegenerative disorder (including dementia), inflammatory
disease, a disorder linked to apoptosis, particularly neuronal apoptosis,
20 autoimmune disease, destructive bone disorder, proliferative disorder, cancer,
infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic
disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin
induced platelet aggregation and/or any condition associated with prostaglandin
endoperoxidase synthase-2.

25 20. A compound or composition as claimed in claim 19, wherein the
neurodegenerative disorder results from apoptosis and/or inflammation.

21. A compound or composition as claimed in claim 19 or claim 20, wherein
30 the neurodegenerative disorder is: dementia; Alzheimer's disease; Parkinson's
disease; Amyotrophic Lateral Sclerosis; Huntington's disease; senile chorea;
Sydenham's chorea; hypoglycemia; head and spinal cord trauma including
traumatic head injury; acute and chronic pain; epilepsy and seizures;

olivopontocerebellar dementia; neuronal cell death; hypoxia-related neurodegeneration; acute hypoxia; glutamate toxicity including glutamate neurotoxicity; cerebral ischemia; dementia linked to meningitis and/or neurosis; cerebrovascular dementia; or dementia in an HIV-infected patient.

5

22. A compound or composition as claimed in claim 19 or 20, wherein the neurodegenerative disorder is a peripheral neuropathy, including mononeuropathy, multiple mononeuropathy or polyneuropathy, such as may be found in diabetes mellitus, Lyme disease or uremia; peripheral neuropathy
10 caused by a toxic agent; demyelinating disease such as acute or chronic inflammatory polyneuropathy, leukodystrophies or Guillain-Barré syndrome; multiple mononeuropathy secondary to a collagen vascular disorder (e.g. polyarteritis nodosa, SLE, Sjögren's syndrome); multiple mononeuropathy secondary to sarcoidosis; multiple mononeuropathy secondary to a metabolic
15 disease (e.g. diabetes or amyloidosis); or multiple mononeuropathy secondary to an infectious disease (e.g. Lyme disease or HIV infection).

23. A compound or composition as claimed in claim 18, wherein the disorder is inflammatory bowel disorder; bronchitis; asthma; acute pancreatitis; chronic
20 pancreatitis; allergies of various types; Alzheimer's disease; autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, glomerulonephritis, scleroderma, chronic thyroiditis, Graves's disease, autoimmune gastritis, diabetes, autoimmune haemolytic anaemia, autoimmune neutropaenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis,
25 ulcerative colitis, Crohn's disease, psoriasis or graft vs host disease.

24. A method of treating or preventing a JNK-mediated disorder in an individual, which method comprises administering to said individual a compound as claimed in any of claims 1-7 or a composition as claimed in any of
30 claims 11-13.

25. A method as claimed in claim 24, wherein the individual is in need of the treatment or prevention of the disorder.

26. A method as claimed in claim 24 or 25, wherein the disorder is a neurodegenerative disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis, autoimmune disease, destructive bone disorder, proliferative disorder, cancer, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin induced platelet aggregation and/or any condition associated with prostaglandin endoperoxidase synthase-2.

10

27. A method as claimed in claim 26, wherein the neurodegenerative disorder results from apoptosis and/or inflammation.

28. A method as claimed in claim 26 or 27, wherein the neurodegenerative disorder is: dementia; Alzheimer's disease; Parkinson's disease; Amyotrophic Lateral Sclerosis; Huntington's disease; senile chorea; Sydenham's chorea; hypoglycemia; head and spinal cord trauma including traumatic head injury; acute and chronic pain; epilepsy and seizures; olivopontocerebellar dementia; neuronal cell death; hypoxia-related neurodegeneration; acute hypoxia; glutamate toxicity including glutamate neurotoxicity; cerebral ischemia; dementia linked to meningitis and/or neurosis; cerebrovascular dementia; or dementia in an HIV-infected patient.

20

29. A method as claimed in claim 26 or 27, wherein the neurodegenerative disorder is a peripheral neuropathy, including mononeuropathy, multiple mononeuropathy or polyneuropathy, such as may be found in diabetes mellitus, Lyme disease or uremia; peripheral neuropathy caused by a toxic agent; demyelinating disease such as acute or chronic inflammatory polyneuropathy, leukodystrophies or Guillain-Barré syndrome; multiple mononeuropathy secondary to a collagen vascular disorder (e.g. polyarteritis nodosa, SLE, Sjögren's syndrome); multiple mononeuropathy secondary to sarcoidosis; multiple mononeuropathy secondary to a metabolic disease (e.g. diabetes or

25

30

amyloidosis); or multiple mononeuropathy secondary to an infectious disease (e.g. Lyme disease or HIV infection).

30. A method as claimed in claim 24, 25 or 26, wherein the disorder is
5 inflammatory bowel disorder; bronchitis; asthma; acute pancreatitis; chronic
pancreatitis; allergies of various types; Alzheimer's disease; autoimmune disease
such as rheumatoid arthritis, systemic lupus erythematosus, glomerulonephritis,
scleroderma, chronic thyroiditis, Graves's disease, autoimmune gastritis, diabetes,
autoimmune haemolytic anaemia, autoimmune neutropaenia, thrombocytopenia,
10 atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis,
ulcerative colitis, Crohn's disease, psoriasis or graft vs host disease.

31. A method as claimed in any of claims 24-30, wherein one or more other
active agent is administered to the individual simultaneously, subsequently or
15 sequentially to administering the compound.

32. A method as claimed in claim 31, wherein the other active agent is an
anti-inflammatory agent such as a p38 inhibitor.

20 33. Use of a compound as defined in claim 1-7 in the manufacture of a
medicament for the prevention or treatment of a JNK-mediated disorder.

34. Use as claimed in claim 33, wherein the disorder is a neurodegenerative
disorder (including dementia), inflammatory disease, a disorder linked to
25 apoptosis, particularly neuronal apoptosis, autoimmune disease, destructive bone
disorder, proliferative disorder, cancer, infectious disease, allergy, ischemia
reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular
hyperplasia, cardiac hypertrophy, thrombin induced platelet aggregation and/or
any condition associated with prostaglandin endoperoxidase synthase-2.

30

35. Use as claimed in claim 34, wherein the neurodegenerative disorder
results from apoptosis and/or inflammation.

36. Use as claimed in claim 34 or 35, wherein the neurodegenerative disorder is: dementia; Alzheimer's disease; Parkinson's disease; Amyotrophic Lateral Sclerosis; Huntington's disease; senile chorea; Sydenham's chorea; hypoglycemia; head and spinal cord trauma including traumatic head injury; acute and chronic pain; epilepsy and seizures; olivopontocerebellar dementia; neuronal cell death; hypoxia-related neurodegeneration; acute hypoxia; glutamate toxicity including glutamate neurotoxicity; cerebral ischemia; dementia linked to meningitis and/or neurosis; cerebrovascular dementia; or dementia in an HIV-infected patient.

10

37. Use as claimed in claim 34 or 35, wherein the neurodegenerative disorder is a peripheral neuropathy, including mononeuropathy, multiple mononeuropathy or polyneuropathy, such as may be found in diabetes mellitus, Lyme disease or uremia; peripheral neuropathy caused by a toxic agent; demyelinating disease such as acute or chronic inflammatory polyneuropathy, leukodystrophies or Guillain-Barré syndrome; multiple mononeuropathy secondary to a collagen vascular disorder (e.g. polyarteritis nodosa, SLE, Sjögren's syndrome); multiple mononeuropathy secondary to sarcoidosis; multiple mononeuropathy secondary to a metabolic disease (e.g. diabetes or amyloidosis); or multiple mononeuropathy secondary to an infectious disease (e.g. Lyme disease or HIV infection).

15
20

38. Use as claimed in claim 34, wherein the disorder is inflammatory bowel disorder; bronchitis; asthma; acute pancreatitis; chronic pancreatitis; allergies of various types; Alzheimer's disease; autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, glomerulonephritis, scleroderma, chronic thyroiditis, Graves's disease, autoimmune gastritis, diabetes, autoimmune haemolytic anaemia, autoimmune neutropaenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis or graft vs host disease.

25
30

39. Use as claimed in any of claims 33-38, wherein the medicament further includes one or more other active agent.

40. Use as claimed in claim 39, wherein the other active agent is an anti-inflammatory agent such as a p38 inhibitor.
- 5 41. An assay for determining the activity of the compounds as defined in any of claims 1-7, comprising providing a system for assaying the activity and assaying the activity of a compound as defined in any of claims 1-7.
- 10 42. An assay as claimed in claim 41, wherein the assay is for the JNK inhibiting activity of the compound, preferably for the JNK3-specific inhibiting activity of the compound.
- 15 43. An assay as claimed in claim 41 or 42, wherein the assay is a Scintillation Proximity Assay (SPA) using radiolabelled ATP, or is ELISA.
44. A method of inhibiting the activity or function of a JNK, particularly JNK3, which method comprises exposing a JNK to a compound as defined in any of claims 1-7 or a composition as defined in any of claims 11-13.
- 20 45. A method as claimed in claim 44, which is performed in a research model.
46. A method as claimed in claim 45, wherein the research model is an animal model.
- 25 47. A compound or a composition substantially as described herein with reference to one or more of the examples.
- 30 48. A method substantially as described herein with reference to one or more of the examples.



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.